Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, with revenue of $481.0 million topping the $402.3 million estimate, +19.6%, as revenue rose ~48% year over year from about $325.7 million. Adjusted EPS of $2.28 topped the $1.79 estimate, +27.4%, and was up from $1.54 a year ago (+48.1% YoY). Profitability remained high, with gross margin at roughly 84% and operating margin near 60%, alongside gross profit of about $401.8 million and operating income of roughly $287.7 million. Net income increased ~39% YoY to about $229.9 million, up from around $165.2 million a year ago. The company generated operating cash flow of about $240.9 million and repurchased roughly $332.7 million of stock during the quarter. Next-period consensus calls for EPS of $2.24 on revenue of $482.3 million.